Research Topics
| Reto BrunSummaryAffiliation: University of Basel Country: Switzerland Publications
| Collaborators
|
Detail Information
Publications
Development of novel drugs for human African trypanosomiasisReto Brun
Department Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, and, University of Basel, CH 4002 Basel, Switzerland
Future Microbiol 6:677-91. 2011..With other screening programs yielding hits, the pipeline for new HAT drugs might finally begin to fill...- Cynaropicrin: the first plant natural product with in vivo activity against Trypanosoma bruceiStefanie Zimmermann
Department of Pharmaceutical Sciences, Division of Pharmaceutical Biology, University of Basel, Klingelbergstrasse 50, Basel, Switzerland
Planta Med 78:553-6. 2012..8, 62, and 9.5 were determined. This is the first report of a plant natural product with potent IN VIVO activity against TRYPANOSOMA BRUCEI... - Human African trypanosomiasisReto Brun
Swiss Tropical Institute, Basel, Switzerland
Lancet 375:148-59. 2010..WHO has stated that if national control programmes, international organisations, research institutes, and philanthropic partners engage in concerted action, elimination of this disease might even be possible... 
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289Tanja Wenzler
Department of Medical Parasitology and Infection Biology, Swiss Tropical Institute, Basel, Switzerland
Antimicrob Agents Chemother 53:4185-92. 2009..In conclusion, DB868 with oral and DB829 with parenteral application are potential candidates for further development of a second-stage African sleeping sickness drug...
Eflornithine for the treatment of human African trypanosomiasisChristian Burri
Swiss Tropical Institute, Swiss Center for International Health, Socinstrasse 57, P O Box, 4002 Basel, Switzerland
Parasitol Res 90:S49-52. 2003..Based on its trypanostatic rather than trypanocidal mode of action, it is a rather slow-acting drug...- Melarsoprol- and pentamidine-resistant Trypanosoma brucei rhodesiense populations and their cross-resistanceSonja C Bernhard
Swiss Tropical Institute, Socinstr 57, Basel, Switzerland
Int J Parasitol 37:1443-8. 2007..The melarsoprol-selected population apparently had lost TbAT1, whereas in the pentamidine-selected trypanosome population it was still present... - New developments in human African trypanosomiasisReto Brun
Swiss Tropical Institute, Parasite Chemotherapy, Basel, Switzerland
Curr Opin Infect Dis 19:415-20. 2006..To review recent literature on human African trypanosomiasis, focussing on genome sequencing, diagnosis and drug discovery, and typing of trypanosomes... - Trematocidal activity of praziquantel and artemisinin derivatives: in vitro and in vivo investigations with adult Echinostoma caproniJennifer Keiser
Swiss Tropical Institute, P O Box, CH 4002 Basel, Switzerland
Antimicrob Agents Chemother 50:803-5. 2006..In vivo, worm burden reductions of 100% were achieved with single oral doses of praziquantel, artesunate, and artemether at 50, 700, and 1,100 mg/kg of body weight, respectively... - Isothermal microcalorimetry, a new tool to monitor drug action against Trypanosoma brucei and Plasmodium falciparumTanja Wenzler
Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland
PLoS Negl Trop Dis 6:e1668. 2012..The method could probably be adapted to other protozoan parasites, especially those growing extracellularly... - Antiparasitic agents: new drugs on the horizonPascal Maser
Swiss Tropical and Public Health Institute, 4003 Basel, Switzerland
Curr Opin Pharmacol 12:562-6. 2012..Thus, finally, new therapeutic agents against malaria and sleeping sickness are within reach... - Identification of a new chemical class of antimalarialsRalf Brunner
Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel CH 4002, Switzerland
J Infect Dis 206:735-43. 2012..falciparum SCID mouse model. ACT-213615 represents a new class of potent antimalarials that merits further investigation for its clinical potential... - Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sicknessMarcel Kaiser
Swiss Tropical and Public Health Institute, Parasite Chemotherapy, Socinstrasse 57, CH 4002 Basel, Switzerland
Antimicrob Agents Chemother 55:5602-8. 2011..b. gambiense and T. b. rhodesiense forms of human sleeping sickness and both stages of the disease... - Human African trypanosomiasisReto Brun
Department Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Socinstrasse 57, CH 4002 Basel, Switzerland
Infect Dis Clin North Am 26:261-73. 2012..Elimination of the disease is considered feasible provided better tools for diagnosis and treatment can be made available... - Bottlenecks and the maintenance of minor genotypes during the life cycle of Trypanosoma bruceiMichael Oberle
Swiss Tropical and Public Health Institute, Basel, Switzerland
PLoS Pathog 6:e1001023. 2010..This is compatible with the epidemic population structure of T. brucei, in which clonal expansion of a few genotypes in a region occurs against a background of frequent recombination between strains... - Spiroindolones, a potent compound class for the treatment of malariaMatthias Rottmann
Swiss Tropical and Public Health Institute, Parasite Chemotherapy, CH 4002 Basel, Switzerland
Science 329:1175-80. 2010..The optimized spiroindolone NITD609 shows pharmacokinetic properties compatible with once-daily oral dosing and has single-dose efficacy in a rodent malaria model... - Antiprotozoal polyacetylenes from the Tanzanian medicinal plant Cussonia zimmermanniiMartin Senn
Department of Chemistry, University of Basel, St Johanns Ring 19, CH 4056 Basel, Switzerland
J Nat Prod 70:1565-9. 2007.... - Antiplasmodial lanostanes from the Ganoderma lucidum mushroomMichael Adams
Institute of Pharmaceutical Biology, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
J Nat Prod 73:897-900. 2010..The lanostanes exhibited in vitro antiplasmodial activity with IC(50) values from 6 to greater than 20 microM... - A protocol for HPLC-based activity profiling for natural products with activities against tropical parasitesMichael Adams
Institute of Pharmaceutical Biology, University of Basel, Klingelbergstrasse 50, CH 4056 Basel, Switzerland
Nat Prod Commun 4:1377-81. 2009..The protocol was validated with extracts and positive controls such as Artemisia annua... - A new double-antibody sandwich ELISA targeting Plasmodium falciparum aldolase to evaluate anti-malarial drug sensitivityLucienne Tritten
Swiss Tropical Institute, Socinstrasse 57, CH 4002 Basel, Switzerland
Malar J 8:226. 2009..Several other ways to evaluate in vitro anti-malarial activity do exist, all with their own assets and limitations... - In vitro assessment of the pharmacodynamic properties of DB75, piperaquine, OZ277 and OZ401 in cultures of Plasmodium falciparumSandra Hofer
Swiss Tropical Institute, Socinstrasse 57, CH 4002 Basel, Switzerland
J Antimicrob Chemother 62:1061-4. 2008....